Finally, PD-L2 expression either on tumor cells or tumor-infiltrating lymphocytes might partly explain the response to anti-PD-1 therapy in PD-L1-negative CCRCC patients [74]. This evidence concerns the gene CD274 and nonpapillary renal cell carcinoma.